Table 1.
The approved RT-targeting drugs
| Generic | Brand | Manufacturer | FDA Approved date | Recommended dose (mg) | Serum half-life (h) |
|---|---|---|---|---|---|
| Nevirapine | Viramune | Boehringer Ingelheim | 21 June, 1996 | 200 b.i.d | 25–30 |
| Delavirdine* | Rescriptor | Upjohn, Pharmacia, Pfizer | 4 April, 1997 | 400 q.d | 2–11 |
| Efavirenz | Sustiva | Bristol-Myers Squibb | 17 September, 1998 | 600 q.d | 40–55 |
| Etravirine | Intelence | Tibotec, Johnson and Johnson | 18 January 2008 | 200 b.i.d | 41 |
| Rilprivine | Edurant | Tibotec, Johnson and Johnson | 20 May, 2011 | 25 q.d | 50 |
| Doravirine | Pifeltro | Merck | 30 August, 2018 | 100 q.d | 11–15 |
The approved drugs generic name, brand name, manufacture, date of approval, recommended daily dosage in mg and serum half-life of the drugs in hours are provided.
*
Discontinued by FDA. q.d: once a day, b.i.d: two times a day.